JP2002508352A5 - ４(３)置換−４(３)−アミノメチル−（チオ）ピラン又はピペリジン誘導体（＝ガバペンチン類似体） - Google Patents

４(３)置換−４(３)−アミノメチル−（チオ）ピラン又はピペリジン誘導体（＝ガバペンチン類似体） Download PDF

Info

Publication number
JP2002508352A5
JP2002508352A5 JP2000538984A JP2000538984A JP2002508352A5 JP 2002508352 A5 JP2002508352 A5 JP 2002508352A5 JP 2000538984 A JP2000538984 A JP 2000538984A JP 2000538984 A JP2000538984 A JP 2000538984A JP 2002508352 A5 JP2002508352 A5 JP 2002508352A5
Authority
JP
Japan
Prior art keywords
pyran
aminomethyl
thio
substituted
piperidine derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000538984A
Other languages
English (en)
Other versions
JP2002508352A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/023991 external-priority patent/WO1999031057A1/en
Publication of JP2002508352A publication Critical patent/JP2002508352A/ja
Publication of JP2002508352A5 publication Critical patent/JP2002508352A5/ja
Abandoned legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項１】 下記式：
【化２９】
Figure 2002508352
［式中、ｎは０〜２の整数であり；
Ｒは下記：
【化３０】
Figure 2002508352
から選択される複素環であり；
Ｘは−Ｏ−、−Ｓ−、−Ｓ(Ｏ)−、−Ｓ(Ｏ)2−またはＮＲ′1であり、ここでＲ′1は水素、炭素原子１〜６個の直鎖または分枝鎖のアルキル、ベンジル、−Ｃ(Ｏ)Ｒ′2（た
だしＲ′2は炭素原子１〜６個の直鎖または分枝鎖のアルキル、ベンジルまたはフェニルである）、または、−Ｃ(Ｏ)2Ｒ′3（ただしＲ′3は炭素原子１〜６個の直鎖または分枝鎖のアルキルまたはベンジルである）であり、ここでベンジルまたはフェニル基は未置換であるか、ハロゲン、トリフルオロメチルおよびニトロから選択される置換基１〜３個で置換されることができる］の化合物または製薬上許容しうるその塩。
JP2000538984A 1997-12-16 1998-11-10 ４（３）置換−４（３）−アミノメチル−（チオ）ピラン又はピペリジン誘導体（＝ガバペンチン類似体）、それらの製法および神経病理学的疾患の治療における使用 Abandoned JP2002508352A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6977397P 1997-12-16 1997-12-16
US60/069,773 1997-12-16
US10490498P 1998-10-20 1998-10-20
US60/104,904 1998-10-20
PCT/US1998/023991 WO1999031057A1 (en) 1997-12-16 1998-11-10 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders

Publications (2)

Publication Number Publication Date
JP2002508352A JP2002508352A (ja) 2002-03-19
JP2002508352A5 true JP2002508352A5 (ja) 2006-01-05

Family

ID=26750407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000538984A Abandoned JP2002508352A (ja) 1997-12-16 1998-11-10 ４（３）置換−４（３）−アミノメチル−（チオ）ピラン又はピペリジン誘導体（＝ガバペンチン類似体）、それらの製法および神経病理学的疾患の治療における使用

Country Status (16)

Country Link
US (1) US6545022B1 (ja)
EP (1) EP1045834A1 (ja)
JP (1) JP2002508352A (ja)
KR (1) KR20010033153A (ja)
CN (1) CN1279667A (ja)
AU (1) AU759392B2 (ja)
BR (1) BR9814287A (ja)
CA (1) CA2304967C (ja)
HU (1) HUP0100069A3 (ja)
IL (1) IL135315A0 (ja)
IS (1) IS5434A (ja)
NO (1) NO20003038L (ja)
NZ (1) NZ503980A (ja)
PL (1) PL341231A1 (ja)
TR (1) TR200001800T2 (ja)
WO (1) WO1999031057A1 (ja)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
AU2002230398A1 (en) 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
MXPA03011566A (es) 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100344A2 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA04004105A (es) * 2002-01-31 2004-11-29 Warner Lambert Co Metodo de tratamiento de tinnitus.
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
JP2005523281A (ja) * 2002-02-22 2005-08-04 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アルファ−２−デルタリガンドとシクロオキシゲナーゼ−２の選択的阻害剤との組合せ
US7026351B2 (en) 2002-03-20 2006-04-11 Xenoport, Inc. Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003239752A1 (en) * 2002-06-27 2004-01-19 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
WO2004052360A1 (en) 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
MXPA05009504A (es) * 2003-03-07 2005-10-18 Warner Lambert Co Derivados de (-aminoacidos sustituidos con tetrazol y oxadiazolona.
EP1622613A4 (en) * 2003-05-14 2008-04-02 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
NZ545884A (en) 2003-09-11 2010-01-29 Xenoport Inc Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
KR100828218B1 (ko) 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
BRPI0414481A (pt) 2003-09-17 2006-11-14 Xenoport Inc métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
RU2377234C2 (ru) * 2003-09-17 2009-12-27 Ксенопорт, Инк. Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк
CA2541752C (en) 2003-10-14 2012-01-03 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
JP2007523202A (ja) * 2004-02-24 2007-08-16 ビオアクソン・テラプティーク・インコーポレーテッド ４置換ピペリジン誘導体
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
US20060025477A1 (en) * 2004-07-22 2006-02-02 Artman Linda D Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
US7691898B2 (en) * 2004-10-08 2010-04-06 Kotobuki Pharmaceutical Co., Ltd. Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia
NZ554737A (en) 2004-11-04 2011-04-29 Xenoport Inc Gabapentin prodrug sustained release oral dosage forms
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
CN101600458A (zh) 2006-12-22 2009-12-09 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
EA201000340A1 (ru) * 2007-08-23 2010-08-30 Новартис Аг Аминобензилзамещенные циклические сульфоны, полезные в качестве ингибиторов васе
US8062870B2 (en) 2008-01-25 2011-11-22 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
US8268887B2 (en) 2008-10-08 2012-09-18 Feng Xu Drug conjugates and methods of use thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
EP2948139B1 (en) 2013-01-28 2019-06-12 Lopez, Hector, L. Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
CN105873580B (zh) 2013-12-17 2020-08-25 埃斯蒂维制药有限公司 加巴喷丁类化合物与σ受体配体的组合物
EP3082782A1 (en) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
WO2019014322A1 (en) 2017-07-11 2019-01-17 BioAxone BioSciences, Inc. KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
EP3793974A4 (en) 2018-05-14 2022-05-04 Xgene Pharmaceutical Inc CRYSTALLINE FORMS OF THE 1-(ACYLOXY)-ALKYL CARBAMATE DRUG CONJUGATE OF NAPROXEN AND PREGABALIN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
AU720628B2 (en) * 1996-02-07 2000-06-08 Warner-Lambert Company Novel cyclic amino acids as pharmaceutical agents
PL341291A1 (en) * 1997-12-16 2001-04-09 Warner Lambert Co 1-substituted derivatives of 1-aminomethyl-ccycloalkanes (gabapentin analogues), their production and application of them in treating neurological disorders

Similar Documents

Publication Publication Date Title
JP2002508352A5 (ja) ４(３)置換−４(３)−アミノメチル−（チオ）ピラン又はピペリジン誘導体（＝ガバペンチン類似体）
JP2002508362A5 (ja) １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体）
JP2003531118A5 (ja)
JP2002543183A5 (ja)
JP2002541233A5 (ja)
EP1797878A3 (en) Benzothiazole derivatives
JP2003528852A5 (ja)
JP2003519676A5 (ja)
JP2002060340A5 (ja)
JP2001519410A5 (ja)
JP2001526218A5 (ja)
JP2003523927A5 (ja)
EP0850926A3 (en) Difluoroprostaglandin derivatives and their use
JP2002332234A5 (ja)
KR920002608A (ko) 라파마이신 유도체
JP2002508361A5 (ja)
JP2002518502A5 (ja)
JP2002525323A5 (ja)
JP2003503449A5 (ja)
JP2002525330A5 (ja)
JP2002535387A5 (ja)
JP2002520286A5 (ja)
JP2003502367A5 (ja)
JP2002506864A5 (ja)
JP2004502732A5 (ja)